Beigene (NASDAQ:ONC) Given "Buy" Rating at Guggenheim

Beigene (NASDAQ:ONC - Get Free Report)'s stock had its "buy" rating restated by Guggenheim in a report issued on Wednesday,Benzinga reports.

Other analysts also recently issued research reports about the company. Sanford C. Bernstein set a $259.00 price objective on Beigene in a report on Thursday, March 13th. JMP Securities set a $348.00 price objective on shares of Beigene in a research note on Friday, February 28th. Royal Bank of Canada started coverage on Beigene in a research report on Monday, April 7th. They issued an "outperform" rating and a $312.00 target price for the company. Macquarie raised their price objective on Beigene from $259.00 to $313.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Finally, Bank of America upgraded Beigene from a "neutral" rating to a "buy" rating and upped their target price for the company from $207.00 to $320.00 in a report on Monday, March 3rd.

Beigene Stock Performance

Shares of ONC stock traded up $2.84 during midday trading on Wednesday, reaching $230.98. 519,865 shares of the company were exchanged, compared to its average volume of 491,582. The business has a 50 day simple moving average of $246.17. The stock has a market capitalization of $22.79 billion, a P/E ratio of -28.03, a P/E/G ratio of 7.73 and a beta of 0.49. Beigene has a 12 month low of $126.97 and a 12 month high of $287.88. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

Beigene (NASDAQ:ONC - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.55). The firm had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. As a group, sell-side analysts predict that Beigene will post -5.82 earnings per share for the current year.

Insider Activity at Beigene

In other news, COO Xiaobin Wu sold 30,654 shares of Beigene stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the company's stock in a transaction dated Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now owns 730,642 shares of the company's stock, valued at $189,966,920. This trade represents a 50.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,146,048 shares of company stock valued at $295,198,300. 7.43% of the stock is owned by corporate insiders.

Beigene Company Profile

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.